Application

PP2 has been used:to analyze the effects of Src/focal adhesion kinase (FAK) signaling on IQ domain GTPase-activating protein 1 (IQGAP1)-mediated anoikis resistancefor Src inhibition to study its effect on epidermal growth factor receptor (EGFR) and nuclear factor erythroid 2-related factor 2 (Nrf2) phosphorylation in non-small cell lung cancer (NSCLC) cellsfor pharmacological inhibition of SRC in MDA-MB-231 breast cancer cells

Biochem/physiol Actions

PP2 is a selective inhibitor of Src-family tyrosine kinases of non-receptor tyrosine kinases (nRTK). It shows >10,000-fold selectivity over Zeta-chain-associated protein kinase 70 (ZAP-70) and Janus kinase 2 (JAK2). PP2 effectively reduces cervical cancer proliferation in vitro and in vivo.

Features and Benefits

This compound was developed by Pfizer. To browse the list of other pharma-developed compounds and Approved Drugs/Drug Candidates, click here.

This compound is a featured product for Kinase Phosphatase Biology research. Click here to discover more featured Kinase Phosphatase Biology products. Learn more about bioactive small molecules for other areas of research at sigma.com/discover-bsm.

Packaging

5 mg in glass bottle